Pharmaceutical growth versus health equity in India: when markets fail
Citations
9 citations
Cites background from "Pharmaceutical growth versus health..."
...But, the knowledge economy fails to take into account the initial inequity that arises due to lack of access to knowledge-bases due to lack of ownership or tenure of forestlands because of repressive government policies (Mukhopadhyay & Paul, 2018)....
[...]
5 citations
5 citations
4 citations
4 citations
References
2,331 citations
"Pharmaceutical growth versus health..." refers background in this paper
...The Hausmann et al. (2011) adolescent fertility rate (births per 100,000 women aged 15–19) was 45 in 2011 (Langer et al. 2015)....
[...]
1,862 citations
"Pharmaceutical growth versus health..." refers background in this paper
...State legitimacy would then subsist as a form of sovereignty limited to guaranteeing economic activity (Lemke 2001; Schiavo 2015)....
[...]
798 citations
"Pharmaceutical growth versus health..." refers background in this paper
...In 2004, public health expenditure as part of GDP was 0.9%, per capita health expenditure was US$ 31, and OOPE as a percentage of private health expenditure was 93.8% (Jain 2010)....
[...]
...According to Balarajan et al. (2011), India accounts for one-fifth of maternal deaths and one-quarter of child deaths in the world....
[...]
...This is despite the fact that communicable diseases, maternal and perinatal conditions, and nutritional deficiencies contribute to 36% of deaths and 42% of disability-adjusted life years in India (Balarajan et al. 2011; Wirtz et al. 2017)....
[...]
...In 2008–09, India’s total expenditure on health was 4.1% of gross domestic product (GDP), with overall public expenditure accounting for 1.10% of GDP (Balarajan et al. 2011; Ginsburg et al. 2017)....
[...]
...Moreover, according to Balarajan et al. (2011), whereas the cost of medicines on the essential drug list rose by 15%, the cost for non-pricecontrolled drugs or those not on the essential drug list rose by 137% between 1996 and 2006....
[...]
637 citations
"Pharmaceutical growth versus health..." refers background in this paper
...…laws based on the moral wellsprings of the multistakeholder social arena, but as demonstrated in the history of the TRIPS regime (Löfgren 2018; Sell 2003), particularly in the context of hegemonic, yet non-altruistic decision-making by the US (Helfer and Austin 2011), states have typically…...
[...]
...As a result, there has been a continuous battle to integrate human rights and development into the TRIPS agreement (Chorev and Shadlen 2015; Gleeson et al. 2015; Sell 2003, 2007; Sell and Prakash 2004; The Corner House 2004)....
[...]
...The result was the establishment of TRIPS in the World Trade Organization (WHO) which signified the emergence of ‘private power leading to public law’ (Johns and Wellhausen 2016; Sell 2003)....
[...]
...As Sell (2003) argues, advanced states in cahoots with their corporations instituted a regime of patents due to heavy protectionist lobbying of their corporate sector, wanting to ensure that any competition undermining their advantage was blocked (Cohen 2008; Cutler and Dietz 2017; Whytock 2016)....
[...]
503 citations